118 related articles for article (PubMed ID: 38533680)
1. Determination of procoagulant activity in human normal immunoglobulin preparations for therapeutic use by FXIa chromogenic assay: Evaluation of test kit sensitivity, reference standard performance and product formulation effects on the FXIa assay.
Behr-Gross ME; Le Tallec D; Sinitskaya N; Milne C; Etscheid M
Pharmeur Bio Sci Notes; 2024; 2024():27-75. PubMed ID: 38533680
[TBL] [Abstract][Full Text] [Related]
2. Detecting factor XIa in immune globulin products: Commutability of international reference materials for traditional and global hemostasis assays.
Liang Y; Jackson JW; Woodle SA; Surov SS; Parunov LA; Scott DE; Weinstein M; Lee TK; Ovanesov MV
Res Pract Thromb Haemost; 2021 Jan; 5(1):211-222. PubMed ID: 33537546
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the ability of the Privigen® purification process to deplete thrombogenic factor XIa from plasma.
Komenda M; Stadler D; Malinas T; Moses M; Pragst I; Herzog E; Schmutz P; Minnig K; El Menyawi I
Vox Sang; 2014 Jul; 107(1):26-36. PubMed ID: 24329163
[TBL] [Abstract][Full Text] [Related]
4. A new manufacturing process to remove thrombogenic factors (II, VII, IX, X, and XI) from intravenous immunoglobulin gamma preparations.
Park DH; Kang GB; Kang DE; Hong JW; Lee MG; Kim KY; Han JW
Biologicals; 2017 Jan; 45():1-8. PubMed ID: 27876270
[TBL] [Abstract][Full Text] [Related]
5. Cation exchange chromatography removes FXIa from a 10% intravenous immunoglobulin preparation.
Kang GB; Huber A; Lee J; Kim MJ; Bang E; Hong J; Park S
Front Cardiovasc Med; 2023; 10():1253177. PubMed ID: 38075963
[TBL] [Abstract][Full Text] [Related]
6. Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products.
Etscheid M; Breitner-Ruddock S; Gross S; Hunfeld A; Seitz R; Dodt J
Vox Sang; 2012 Jan; 102(1):40-6. PubMed ID: 21545600
[TBL] [Abstract][Full Text] [Related]
7. Enabling accurate measurement of activated factor XI (FXIa) in therapeutic immunoglobulin products.
Wilmot HV; Gray E
Vox Sang; 2021 Jul; 116(6):656-664. PubMed ID: 33277936
[TBL] [Abstract][Full Text] [Related]
8. In vitro evaluation of residual procoagulants in human intravenous immunoglobulins from 11 Chinese blood fractionation companies.
Ma L; Sun P; Lin F; Diao G; Li C
Thromb Res; 2013 Sep; 132(3):381-5. PubMed ID: 23953595
[TBL] [Abstract][Full Text] [Related]
9. Optimization of the thrombin generation test components to measure potency of factor VIII concentrates.
Jha NK; Shestopal SA; Gourley MJ; Woodle SA; Liang Y; Sarafanov AG; Weinstein M; Ovanesov MV
Haemophilia; 2016 Sep; 22(5):780-9. PubMed ID: 27038076
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the thrombin generation profiles of four different rFVIII products in FVIII-deficient plasma using FIXa and FXIa activation.
Brophy DF; Martin EJ; Ninivaggi M; Mohammed BM; Barrett JC; Kuhn J; Nolte ME; Waters EK; Ezban M
Haemophilia; 2018 Sep; 24(5):815-822. PubMed ID: 30112856
[TBL] [Abstract][Full Text] [Related]
11. Combined thrombogenic effects of vessel injury, pregnancy and procoagulant immune globulin administration in mice.
Xu Y; Liang Y; Parunov L; Despres D; Eckhaus M; Scott D; Ovanesov M; Struble EB
Thromb J; 2020 Nov; 18(1):32. PubMed ID: 33292285
[TBL] [Abstract][Full Text] [Related]
12. An application of mass spectrometry for quality control of biologicals: Highly sensitive profiling of plasma residuals in human plasma-derived immunoglobulin.
Limonier F; Van Steendam K; Waeterloos G; Brusselmans K; Sneyers M; Deforce D
J Proteomics; 2017 Jan; 152():312-320. PubMed ID: 27894965
[TBL] [Abstract][Full Text] [Related]
13. Calibration of the WHO 5th IS for Blood Coagulation Factor IX, Concentrate and Ph. Eur. Human Coagulation Factor IX Concentrate Biological Reference Preparation Batch 3 and investigation of the suitability of an IS as potency standard for purified full-length recombinant FIX.
Gray E; Hogwood J; Dougall T; Rigsby P; Matejtschuk P; Terao E
Pharmeur Bio Sci Notes; 2021; 2021():26-68. PubMed ID: 33783349
[TBL] [Abstract][Full Text] [Related]
14. Quantitative determination of activated coagulation factor XI as an impurity in therapeutic immunoglobulins from Chinese blood fractionation companies.
Ma L; Sun P; Lin FZ; Diao G; Li CQ
Genet Mol Res; 2013 Jul; 12(3):2556-61. PubMed ID: 23315876
[TBL] [Abstract][Full Text] [Related]
15. Collaborative study for the establishment of the WHO 3(rd) International Standard for Endotoxin, the Ph. Eur. endotoxin biological reference preparation batch 5 and the USP Reference Standard for Endotoxin Lot H0K354.
Findlay L; Desai T; Heath A; Poole S; Crivellone M; Hauck W; Ambrose M; Morris T; Daas A; Rautmann G; Buchheit KH; Spieser JM; Terao E
Pharmeur Bio Sci Notes; 2015; 2015():73-98. PubMed ID: 26830160
[TBL] [Abstract][Full Text] [Related]
16. Absence of in vitro Procoagulant Activity in Immunoglobulin Preparations due to Activated Coagulation Factors.
Oviedo AE; Bernardi ME; Guglielmone HA; Vitali MS
Transfus Med Hemother; 2015 Nov; 42(6):397-402. PubMed ID: 26733772
[TBL] [Abstract][Full Text] [Related]
17. Flebogamma(®) DIF (intravenous immunoglobulin) purification process effectively eliminates procoagulant activities.
José M; Marzo N; Pons B; Herrerias A; López L; Faro M; López M; Jorquera JI
Biologicals; 2013 Nov; 41(6):393-9. PubMed ID: 24051302
[TBL] [Abstract][Full Text] [Related]
18. Assessment of immunoglobulin concentrates on thrombogenic activity by thrombin generation assay, prekallikrein activator assay, and size-exclusion chromatography.
Seifner A; Beck G; Bayer P; Eichmeir S; Lackner F; Rögelsperger O; Weber K; Wollein G
Transfusion; 2014 Feb; 54(2):376-83. PubMed ID: 23772713
[TBL] [Abstract][Full Text] [Related]
19. Assay discrepancies using human coagulation factor VIII chromogenic kits: Results from a plasma-derived factor VIII collaborative study (BSP112).
Raut S; Daas A; Rigsby P; Costanzo A
Pharmeur Bio Sci Notes; 2023; 2023():1-14. PubMed ID: 37272308
[TBL] [Abstract][Full Text] [Related]
20. Thrombin generation test based on a 96-channel pipettor for evaluation of FXIa procoagulant activity in pharmaceuticals.
Parunov LA; Shea ME; Liang Y; Surov SS; Chattopadhyay M; Lee TK; Scott DE; Ovanesov MV
Nat Protoc; 2021 Aug; 16(8):3981-4003. PubMed ID: 34215864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
